These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 239460)

  • 41. The effect of platelets in the activation of human blood coagulation factor IX by factor XIa.
    Soons H; Janssen-Claessen T; Hemker HC; Tans G
    Blood; 1986 Jul; 68(1):140-8. PubMed ID: 3487352
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa.
    Braunstein KM; Noyes CM; Griffith MJ; Lundblad RL; Roberts HR
    J Clin Invest; 1981 Dec; 68(6):1420-6. PubMed ID: 6976355
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Isolation of the high molecular form of bovine factor X and some of its physical properties.
    Yue RH; Gertler MM
    Biochim Biophys Acta; 1977 Feb; 490(2):350-62. PubMed ID: 836878
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structural changes accompanying enzymatic activation of human Hageman factor.
    Revak SD; Cochrane CG; Johnston AR; Hugli TE
    J Clin Invest; 1974 Sep; 54(3):619-27. PubMed ID: 4277669
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Purification and characterization of kallikrein from plasma of patients with acute pancreatitis.
    Toki N; Sumi H; Takasugi S
    Clin Sci (Lond); 1981 Feb; 60(2):199-205. PubMed ID: 6165511
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interrelations between the clotting and kinin systems. Activation of factor VII involving prekallikrein-kallikrein. A review.
    Stormorken H; Gjoennaess H; Laake K
    Haemostasis; 1973-1974; 2(6):245-52. PubMed ID: 4278152
    [No Abstract]   [Full Text] [Related]  

  • 47. [Blood protein technological industrial developments as a mirror of fundamental studies bgy the Institute of Biochemistry of the Ukrainian National Academy of Sciences].
    Volkov GL; Andrianov SI; Horoshnykova TV; Borysevych OS; Gavryliuk OS
    Ukr Biokhim Zh (1999); 2000; 72(4-5):109-21. PubMed ID: 11200439
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Isolation and characterization of human factor VII. Activation of factor VII by factor Xa.
    Bajaj SP; Rapaport SI; Brown SF
    J Biol Chem; 1981 Jan; 256(1):253-9. PubMed ID: 6778860
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Studies on immunological assay of vitamin-K dependent factors. III. A double monoclonal immunoradiometric assay for factor IX antigen.
    Mikami S; O'Brien DP; Mellars G; Goodall AH; Tuddenham EG
    Br J Haematol; 1986 Mar; 62(3):513-24. PubMed ID: 3485443
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Purification and properties of human factor IXa.
    Váradi K; Elödi S
    Thromb Haemost; 1976 Jun; 35(3):576-85. PubMed ID: 10636
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factor IX is activated in vivo by the tissue factor mechanism.
    Bauer KA; Kass BL; ten Cate H; Hawiger JJ; Rosenberg RD
    Blood; 1990 Aug; 76(4):731-6. PubMed ID: 2383653
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of calcium ions and the heavy chain of factor XIa in the activation of human coagulation factor IX.
    Sinha D; Seaman FS; Walsh PN
    Biochemistry; 1987 Jun; 26(13):3768-75. PubMed ID: 3498513
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Kinetics of the Factor XIa catalyzed activation of human blood coagulation Factor IX.
    Walsh PN; Bradford H; Sinha D; Piperno JR; Tuszynski GP
    J Clin Invest; 1984 May; 73(5):1392-9. PubMed ID: 6609171
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activation of human factor X (Stuart factor) by a protease from Russell's viper venom.
    Di Scipio RG; Hermodson MA; Davie EW
    Biochemistry; 1977 Nov; 16(24):5253-60. PubMed ID: 921929
    [No Abstract]   [Full Text] [Related]  

  • 55. Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography.
    Burnouf T; Michalski C; Goudemand M; Huart JJ
    Vox Sang; 1989; 57(4):225-32. PubMed ID: 2617959
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proteolysis of factor B by plasma kallikrein and plasmin.
    Ikari N; Niinobe M; Fujii S
    FEBS Lett; 1981 Aug; 131(1):143-6. PubMed ID: 6456937
    [No Abstract]   [Full Text] [Related]  

  • 57. Regulation of the tertiary structure and function of coagulation factor IX by magnesium (II) ions.
    Sekiya F; Yamashita T; Atoda H; Komiyama Y; Morita T
    J Biol Chem; 1995 Jun; 270(24):14325-31. PubMed ID: 7782291
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alternative pathways of thromboplastin-dependent activation of human factor X in plasma.
    Marlar RA; Griffin JH
    Ann N Y Acad Sci; 1981; 370():325-35. PubMed ID: 6943963
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Factor IX Kawachinagano: impaired function of the Gla-domain caused by attached propeptide region due to substitution of arginine by glutamine at position -4.
    Sugimoto M; Miyata T; Kawabata S; Yoshioka A; Fukui H; Iwanaga S
    Br J Haematol; 1989 Jun; 72(2):216-21. PubMed ID: 2757966
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Blood clotting factor IX Nagoya 3: the molecular defect of zymogen activation caused by an arginine-145 to histidine substitution.
    Suehiro K; Miyata T; Takeya H; Takamatsu J; Saito H; Murakawa M; Okamura T; Niho Y; Iwanaga S
    Thromb Res; 1990 Nov; 60(4):311-20. PubMed ID: 2087690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.